TITLE

Effect of Maintaining Highly Active Antiretroviral Therapy on AIDS Events among Patients with Late-Stage HIV Infection and Inadequate Response to Therapy

AUTHOR(S)
Gandhi, Tejal; Wei Wei; Amin, Kamal; Kazanjian, Powel
PUB. DATE
March 2006
SOURCE
Clinical Infectious Diseases;3/15/2006, Vol. 42 Issue 6, p878
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. We evaluated the effect of maintaining highly active antiretroviral therapy (HAART) on the development of new acquired immunodeficiency syndrome (AIDS)-related events in patients with late-stage human immunodeficiency virus (HIV) infection who had suboptimal CD4+ cell count and viral load responses to HIV therapy. Methods. In patients with pretreatment CD4+ cell counts of <200 cells/mm³, incidence rates of new AIDS-related events occurring during HIV treatment were calculated during period 1 (pre-HAART era, 1990-1995; 88 patients) and period 2 (HAART era, 1996-2004; 214 patients) according to CD4+ cell count responses while receiving treatment. Cox multivariate model was used to compare rates of AIDS-related events from period 2 with those from period 1 according to specific CD4+ cell count response categories and rates of AIDS-related events for various viral load ranges within CD4+ cell count categories during period 2. Results. For period 2 patients with CD4+ cell counts <50 cells/mm³ and viral loads >100,000 copies/mL, the rate of AIDS-related events (39.3 events per 100 person-years) was significantly lower than that for period 1 patients with CD4+ cell counts <50 cells/mm³ (76.4 events per 100 person-years; P = .02). This held true for patients with CD4+ cell counts <100 cells/mm³ there were also significantly fewer AIDS-related events in period 2 (18 events per 100 person-years) than in period 1 (65.2 events per 100 person-years; P = .001), including those events occurring among period 2 patients with viral loads >100,000 copies/mL (29.5 events per 100 person-years; P = .01). Similarly, for patients with CD4+ cell counts of 100-200 cells/mm³, there were fewer AIDS-related events in period 2 (7.8 events per 100 person-years) than in period 1 (34.5 events per 100 person-years; P = .001); even for patients in period 2 with viral loads >100,000 copies/mL (15.4 events per 100 person-years; P = .04). Conclusions. Our data suggest that, even among patients with late-stage HIV infection and inadequate CD4+ cell count and viral load responses to HIV therapy, maintaining HAART may reduce the incidence of AIDS-related events.
ACCESSION #
19957753

 

Related Articles

  • Prevalence and Clinical Implications of Interactive Toxicity Beliefs Regarding Mixing Alcohol and Antiretroviral Therapies among People Living with HIV/AIDS. Kalichman, Seth C.; Amaral, Christina M.; White, Denise; Swetsze, Connie; Pope, Howard; Kalichman, Moira O.; Cherry, Chauncey; Eaton, Lisa // AIDS Patient Care & STDs;Jun2009, Vol. 23 Issue 6, p449 

    Alcohol use is a barrier to medication adherence. Beyond the cognitive effects of intoxication, people living with HIV/AIDS who believe that alcohol should not be mixed with their medications may temporarily stop taking medications when drinking. To examine the effects of alcohol-treatment...

  • Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study. Young, Jim; Bucher, Heiner C.; Battegay, Manuel; De Geest, Sabina; Spirig, Rebecca; Flepp, Markus; Rickenbach, Martin; Furrer, Hansjakob; Bernasconi, Enos; Hirschel, Bernard; Telenti, Amalio; Vernazza, Pietro // BMJ: British Medical Journal (International Edition);1/3/2004, Vol. 328 Issue 7430, p15 

    Presents a paper on stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy.

  • Retrospective Analysis of Suspending HAART in Selected Patients with Controlled HIV Replication. Jacobs, Benjamin; Neil, Nancy; Aboulafia, David M. // AIDS Patient Care & STDs;Jul2005, Vol. 19 Issue 7, p429 

    We sought to determine the consequences of stopping highly active antiretroviral therapy (HAART) in a group of 41 HIV-infected individuals with undetectable HIV viral loads and CD4+ counts greater than 500 cells per microliter for 6 months or more. Clinical and laboratory parameters were...

  • Structured Intermittent Therapy with Seven-Day Cycles of HAART for Chronic HIV Infection: A Pilot Study in São Paulo, Brazil. Casseb, Jorge; Da Silva Duarte, Alberto Jos // AIDS Patient Care & STDs;Jul2005, Vol. 19 Issue 7, p425 

    In the last 6 years, an impressive impact of the highly active antiretroviral therapy (HAART) on survival and morbidity in HIV-1–infected individuals has been attained. However, their prolonged use may induce metabolic adverse effects such as lipodistrophy, hypertension, diabetes...

  • Hepatitis C Virus (HCV) Quasispecies Complexity and Selection in HCV/HIV-Coinfected Subjects Treated with Interferon-Based Regimens. Sherman, Kenneth E.; Rouster, Susan D.; Stanford, Sandra; Blackard, Jason T.; Shire, Norah; Koziel, Margaret; Peters, Marion; Chung, Raymond T. // Journal of Infectious Diseases;3/1/2010, Vol. 201 Issue 5, p712 

    Background. Coinfection with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) has emerged as a major cause of morbidity and mortality due to liver disease. Interferon-based therapy response rates have been disappointingly low. Baseline HCV complexity and the relationship between...

  • superinfection a changing picture. Duffin, Ross // HIV Australia;Jun-Aug2004, Vol. 3 Issue 4, p9 

    Discusses the impact of superinfection on an individual's HIV disease progression. Overview of several HIV superinfection cases in Australia; Frequency of the occurrence of superinfection; Recommended approach to prevent HIV superinfection.

  • Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. Gibb, D.M.; Duong, T; Farrelly, L; Dunn, D.T.; Tookey, P.A.; Masters, J; Peckham, C.S.; Sharland, M; Tudor-Williams, G; Novelli, V; Buffer, K; Riordan, A // BMJ: British Medical Journal (International Edition);11/1/2003, Vol. 327 Issue 7422, p1019 

    Abstract Objective: To describe changes in demographic factors, disease progression, hospital admissions, and use of antiretroviral therapy in children with HIV. Design: Active surveillance through the national study of HIV in pregnancy and childhood (NSHPC) and additional data from a subset of...

  • Impact of Indinavir on the Quality of Life in Patients with Advanced HIV Infection Treated with Zidovudine and Lamivudine. Coplan, Paul M.; Cook, John R.; Carides, George W.; Heyse, Joseph F.; Wu, Albert W.; Hammer, Scott M.; Nguyen, Bach-Yen; Meibohm, Anne R.; DiNubile, Mark J. // Clinical Infectious Diseases;8/1/2004, Vol. 39 Issue 3, p426 

    Objective. in AIDS Clinical Trial Group (ACTG) study 320, triple-combination antiretroviral therapy including indinavir significantly slowed progression to acquired immunodeficiency syndrome or death, compared with treatment with dual nucleoside reverse-transcriptase inhibitors (NRTIs) alone, in...

  • Hope and hype.  // Network Magazine of the Canadian Women's Health Network;Winter1998/1999, Vol. 2 Issue 1, p3 

    Relates how the author decided to go on combination therapy to combat HIV-related symptoms. Author's initial refusal to take any AIDS drugs; Details of how the author reached the decision to try a combination of AIDS drugs; Author's daily medication routine; Effects of the combination therapy.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics